Is My Prednisolone Acetate Eye Drop Recalled? Lot Check
Match your bottle’s maker, size, NDC and lot to the 2026 Lupin recall, then learn what to do if the label matches or cannot be verified.
The June 2026 recall covers 2,530,182 bottles, but it does not cover prednisolone acetate as a drug or every generic version. It applies to specified lots of Lupin prednisolone acetate ophthalmic suspension USP 1% in 5, 10 and 15 mL bottles. Your manufacturer, bottle size, package NDC, lot and expiration must match the recall record before the bottle can be treated as affected. The FDA-hosted enforcement data identify the product, quantity and recall.
Lupin Pharmaceuticals initiated the voluntary recall on June 4, 2026. FDA classified it as Class II on June 30, 2026 under recall number D-0655-2026 and event ID 99144. The action is recorded as “Voluntary: Firm initiated,” not FDA-mandated.
Select the maker, size and codes printed on your bottle; the checker shows whether the Lupin recall remains a possible match.
This screens the maker, strength, package NDC, overall lot envelope and reported expiration period. A potential match still needs confirmation in the complete size-specific FDA record.
Confirm HA00937 and its expiration in the current 5 mL FDA lot entry before treating the bottle as an exact match.
All Three Named Package Configurations
| Size | Package NDC | Supplied Lot Information | What It Establishes |
|---|---|---|---|
| 5 mL | 70748-332-02 | HA00937–HC00068 overall envelope | Exact 5 mL lot list required |
| 10 mL | 70748-332-03 | HA00937–HC00068 overall envelope | Exact 10 mL lot list required |
| 15 mL | 70748-332-04 | HA00937–HC00068 overall envelope | Exact 15 mL lot list required |
The overall span does not prove that every intervening lot was recalled in every size. The supplied FDA excerpt is truncated and includes one ambiguous-looking code, so this tool does not silently reconstruct a complete lot list.
Verify the exact size-specific lot and expiration, then contact the pharmacy or prescriber.
This particular Lupin recall does not identify the bottle by the entered fields.
Ask for help when a maker, NDC, lot or expiration is unreadable.
Source: FDA/openFDA enforcement data for recall D-0655-2026, event 99144. Recall initiated June 4, 2026; Class II classification dated June 30, 2026.
The checker is a screening tool, not a substitute for the complete lot record. The supplied FDA extract establishes an overall affected-lot span of HA00937 through HC00068, but it does not provide a clean, complete size-by-size lot table. A code within that envelope still requires exact verification against the current FDA record.
The Consensus Is Understandable but Too Broad
The broad reaction to a headline saying “2.5 million bottles recalled” is understandable. Prednisolone acetate is a prescription steroid often used on a schedule that may vary by the condition being treated, and patients reasonably do not want to use a potentially defective bottle. A large nationwide recall deserves prompt attention.
The mistake is treating the medication name as the recall test. The action names one manufacturer’s 1% ophthalmic suspension and specified lots in three package configurations. It does not name every manufacturer of generic prednisolone acetate, every corticosteroid eye drop or every Lupin production lot. The Lupin-specific FDA-hosted result identifies Lupin Limited as the manufacturer and Lupin Pharmaceuticals Inc. as the recalling firm.
The consensus is right about one point: a bottle that appears to match should not be dismissed because no symptoms or visible particles are present. But the response should be verification and prompt professional guidance—not independently stopping every product labeled prednisolone acetate.
Match the Manufacturer, Size and Package NDC
The recalled product is labeled prednisolone acetate ophthalmic suspension USP 1%, sterile and prescription only. These are the three named bottle configurations:
| Bottle Size | Package NDC |
|---|---|
| 5 mL | 70748-332-02 |
| 10 mL | 70748-332-03 |
| 15 mL | 70748-332-04 |
The final package segment matters. The shorter product-level NDC 70748-332 does not distinguish among the three bottle sizes.
An NDC match is only a first screen. A 5 mL bottle with NDC 70748-332-02 still needs a matching lot and expiration. A 10 mL bottle with a different package NDC is not identified by this particular Lupin action. A product from another manufacturer is not included merely because it contains the same drug.
Check the label for all six identifiers:
- Manufacturer: Lupin Limited, Lupin Pharmaceuticals Inc. or labeling that otherwise connects the product to Lupin.
- Product: Prednisolone acetate ophthalmic suspension USP.
- Strength: 1%.
- Bottle size: 5, 10 or 15 mL.
- Package NDC: The complete size-specific number.
- Lot and expiration: Copied exactly from the bottle or carton.
Preserve every letter and number in the lot code. Do not guess whether a faint character is A, 0 or O. A matching expiration period without a matching lot does not confirm a recall.
The reported expirations associated with affected entries extend from July 31, 2026, through March 31, 2028, depending on the lot and bottle size. That broad period is not an independent test: many unaffected bottles could expire within it.
The Published Lot Span Is Not a Complete Lot List
The affected codes span HA00937 through HC00068, but that beginning-to-end range is an envelope, not proof that every intervening code was recalled for every bottle size. Confirmation requires the size-specific list and corresponding expiration in the complete enforcement record.
The supplied openFDA excerpt cuts off within the lot field. It also displays one entry as H00973 among otherwise similarly formatted HA codes. The available evidence does not establish whether that difference is intentional or a transcription issue, so it should not be silently corrected.
Use the specific FDA enforcement record for the Lupin product for the bottle-level comparison. Find the section for your bottle size, compare the lot character by character and confirm the associated expiration. If a character or entry remains ambiguous, ask the dispensing pharmacy or prescriber to verify it rather than guessing.
You can also search by recall number D-0655-2026 or event ID 99144. Do not compare a 5 mL bottle with the lot section for a 10 or 15 mL package.
OpenFDA warns that its results should be assumed to be unvalidated and should not be relied upon for medical-care decisions. The data identify the enforcement action; a pharmacist or clinician should address dosing, replacement and bottle handling.
A Match, Mismatch and Unreadable Label Require Different Responses
Every Identifier Matches
An exact match means the manufacturer, product, strength, size, package NDC, lot and expiration all correspond to the FDA record.
Contact the dispensing pharmacy or prescribing ophthalmologist, optometrist or other clinician promptly. Ask whether the bottle is included, what to do about the next scheduled dose, how to obtain an appropriate replacement and how the bottle should be handled.
Do not use this page as an instruction to skip a dose, continue using a matching bottle, discard it or return it in a particular way. Those decisions depend on professional guidance and the reason the steroid was prescribed. A clinician quoted by UC Davis Health advises patients whose Lupin bottles appear on the list to contact the prescribing physician immediately for a replacement; the report also notes that dosing duration and frequency vary by condition. UC Davis Health provides guidance for affected patients.
The available evidence does not establish one universal refund, return, replacement or disposal process.
A Required Identifier Does Not Match
If the manufacturer is not Lupin, the package NDC differs from all three configurations, or the lot is absent from the current size-specific record, this particular Lupin recall does not identify the bottle as affected.
That is a narrow result. It does not rule out another recall, a separate product problem or a clinical concern. If the label names another manufacturer or medicine, search current FDA information using those printed identifiers.
When only one field differs, transcribe it again before deciding. Pay particular attention to the final package-NDC digits and similar-looking lot characters.
A Code Is Missing or Unreadable
An unreadable manufacturer, NDC, lot or expiration leaves the recall status unresolved. The medication name, cap color, carton appearance, an online image or an expiration within the broad date period cannot replace the missing identifier.
If the carton is gone, use the bottle and remaining prescription packaging. Ask the dispensing pharmacy for help identifying the product, but do not assume it retained the exact lot number. The prescriber’s office can also help determine what to do if verification cannot be completed before the next scheduled dose.
The Recall Concerns a Foreign Substance
The official reason is “Presence of Foreign Substance.” The supplied evidence does not establish the substance’s composition, source, size or effect in any individual bottle.
FDA classified the action as Class II. That classification means use of or exposure to the affected product may cause temporary or medically reversible adverse health consequences, while the probability of serious adverse consequences is considered remote. Optometry Advisor reports the quantity, reason, configurations and classification.
Class II does not mean that every recalled bottle contains visible material, that a matching bottle caused an injury or that the action can be ignored. It also does not supply individualized treatment instructions. FDA’s general recall guidance explains that drug recalls are commonly voluntary company actions to remove a defective medicine or warn about a potential risk. FDA explains how drug recalls work.
The regulatory sequence here is specific: Lupin initiated the recall, and FDA later assigned the classification.
The supplied openFDA dataset was last updated August 19, 2026, when it listed the recall as ongoing. That extract does not independently establish the status on a later date.
New Eye Symptoms Need Clinical Evaluation
Recall verification and symptom evaluation answer different questions. The bottle codes determine whether the product matches an enforcement record. A clinician determines what is causing a symptom and how urgently it should be treated.
Seek prompt eye-care advice for eye pain, a new or sudden vision change, marked redness, unusual discharge, swelling around the eye or light sensitivity. Under Dry Eye Watch’s general safety notice, sudden vision change, eye pain or light sensitivity warrants same-day clinician attention. Depending on availability and severity, that may mean contacting an ophthalmologist, optometrist, prescribing clinician or an appropriate urgent eye-care service. The Dry Eye Watch Terms of Use explain that the site provides general information rather than diagnosis.
Symptoms do not prove that a bottle is recalled, and a recall match does not prove that the product caused a symptom. If you see unexpected material in the bottle, describe what you observed to the pharmacy and an eye-care professional rather than attempting to identify it yourself.
Not Every Prednisolone Product Is Part of This Action
This recall does not establish that every prednisolone acetate drop, every ophthalmic steroid or every product from another manufacturer is affected. It also should not be combined with separate recalls involving different brands, lots, reasons or classifications.
Absence from a shortened news list, screenshot, third-party checker or truncated search result does not prove that a bottle is unaffected. Conversely, sharing the drug name with Lupin’s product does not make another manufacturer’s bottle part of this recall.
The defensible bottle-level result is one of three:
- Exact match: Contact the pharmacy or prescriber promptly for confirmation and instructions.
- Clear mismatch: This specific Lupin recall does not identify the bottle as affected.
- Missing or ambiguous information: The status remains unresolved until the codes are verified.
Do not independently change a prescribed steroid schedule based on the headline or this checker. Match the complete label, use the current FDA record and obtain individualized guidance when the bottle matches or cannot be classified.